China's Hengrui Pharma has out-licensed ex-China rights for myocardial myosin inhibitor HRS-1893 to US-based Braveheart Bio in a deal worth up to USD 1.09 billion, including USD 65 million upfront with equity component and USD 1.01 billion in milestones. The selective ATPase inhibitor normalises cardiac contraction and reduces left ventricular hypertrophy, with Phase III trials underway for obstructive hypertrophic cardiomyopathy following positive Phase I data released this year.

Braveheart Bio was established in 2024 with backing from Forbion and OrbiMed to develop cardiovascular therapies. This represents Hengrui's second NewCo partnership after its USD 6 billion GLP-1 deal with Bain Capital and Atlas Ventures in May 2024. Hengrui maintains over 10 cardiovascular assets in clinical development including SHR-6934 and SHR-4658 for heart failure, strengthening its position in cardiology innovation beyond traditional oncology focus.

PharmCube's NextBiopharm® database shows Hengrui has so far entered nearly 20 deals as transferor. Click here to request a free trial for NextBiopharm®.